Landsverk HB, Sandquist LE, Bay LTE, Hauge S, van Bijsterveldt L, Lindbergsengen L, Lund-Andersen C, Kanduri C, Lyng H, Fjeldbo CS, Hompland T, Humphrey TC, Syljuåsen RG(2026) Transcription termination counteracts DNA damage after WEE1 inhibition Nucleic Acids Res, 54(3) DOI 10.1093/nar/gkaf1487, PubMed 41569153
Fernandez Salamanca M, van Houdt PJ, Hompland T, Deręgowska-Cylke M, van Leeuwen PJ, van der Poel HG, Bekers E, Guimaraes MAS, Lyng H, van der Heide UA, Schoots IG(2025) Hypoxia and cribriform growth in prostate cancer - establishing a link via MRI BMC Med Imaging, 26(1), 32 DOI 10.1186/s12880-025-02084-3, PubMed 41366753
Skipar K, Hompland T, Lund KV, Fjeldbo CS, Lindemann K, Hellebust TP, Lyng H, Bruheim K(2025) Tolerability, safety and feasibility of metformin combined with chemoradiotherapy in patients with locally advanced cervical cancer: A phase II, randomized study Acta Oncol, 64, 439-447 DOI 10.2340/1651-226X.2025.43045, PubMed 40105683
Heidi Lyng, Department of Radiation Biology, Institute for Cancer Research Norwegian Radium Hospital, Oslo University Hospital Phone +47 22 78 1478, e-mail: heidi.lyng@ous-hf.no
